Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
KALY and GNBT Could Give GWPH Run For Money In 2019 - See Motley Fool Prediction
Print
New York, NY -- December 24, 2018 -- InvestorsHub NewsWire -- via nextbigticker.com -- Kali, Inc. (dba/Kali-Extracts) (USOTC: KALY) and Generex Biotechnology Corp (OTCQB: GNBT) through a deal announced between GNBT and US Cannabis Health, a Joint Venture partnership between KALY and Puration, Inc. (USOTC: PURA) and Nouveau Life Pharmaceuticals (USOTC: NOUV) could potentially soon introduce a cannabis drug that not only rivals GW Pharmaceuticals’ (NASDAQ: GWPH) Epidiolex, KALY and GNBT’s cannabis drug development could reveal that GWPH’s Epidiolex infringes on GNBT patents.
"I believe the underlying value of Kali-Extracts cannabis biotechnology properties are as of yet unrecognized by the market," said Frederick Ferri, CEO of Kali-Extracts. "Doctors involved in research with our extracts have given me feedback that our extracts are superior to those of GW Pharmaceuticals [GW Pharmaceuticals, plc (GWPH)]. As just one example of what our cannabis biotechnology can lead to, I believe our developing COPD therapies in combination with the potential for us to harness the patented RapidMist buccal cavity drug administration technology of Generex [Generex Biotechnology, Corp. (GNBT)] through our US Cannabis Health partnership, would put Kali-Extracts in front of any cannabis biotechnology company on the market. For that matter, I think Generex applying its patented RapidMist buccal cavity administration technology would bode well for Generex as well. I also happen to think that the combination of our COPD technology with the RapidMist technology of Generex would illustrate that GW Pharmaceuticals buccal drug administration is likely an infringement on Generex's RapidMist patent. In summary, the market has a lot yet to learn about Kali-extracts cannabis biotechnology. I hope the COPD example herein begins to give a glimpse of that yet to be realized value. Finally, I think the developing partnership between KALY and its other US Cannabis Health partners with Generex can put KALY, its other US Cannabis Health partners and Generex on top of their respective markets." (source - yahoo.com)
KALY and GNBT could impact Motley Fool’s 2019 prediction for GWPH. See Motley Fool’s prediction #4 of 7 for cannabis stocks in 2019:
4. First U.S. plant-based cannabinoid drug is a big hit, Big Pharma execs injure themselves after slapping foreheads in regret
Despite some nattering negativism by skeptics, GW Pharmaceuticals' (NASDAQ: GWPH) Epidiolex, the first plant-based cannabinoid drug approved in the U.S., becomes a smashing commercial success. Even pessimistic analysts project that Epidiolex likely will become a blockbuster within a few years.
As Epidiolex sales steadily increase, several renowned Big Pharma executives are forced to receive medical care for injuries received from slapping themselves on the foreheads in regret. These slaps stem from the executives reading the histories of their companies marketing cannabis-based drugs in the early 20th century. (Source: Motley Fool)
thanks for posting that. read it twice. looks like we need that goldman report to help with getting the ce removed. the report will help get the otc all the info they need to become current. glad the company made that statement. makes them look more transparent and shows concern for the investors. any company that did not care or was just a scam would not put that out. and spend the money on the goldman report to get it done. thanks again.
trust me I am sitting back and enjoying this or I would have sold. Friday seemed like a nice strong close so looking for a good open tomorrow. like I have said before the only 2 things bothering me for the moment is I believe kaly should have said something on why the goldman report did not come out and I am sure they have spoken to the otc. so when do they expect the ce to come down or is there any other info they are getting together for them to get the ce removed. the more transparent they are the better they will look.
I wish it was over 3 I have an average of .0012 have not sold a single share. tomorrow morning when pre market starts the bid and ask will tell all. nothing we post will change that. glta.
like I said look at the bid and ask. we all see the t trades after hours. those where trades that where done Thursday but not reported until Friday after the market closed. look at the bid and ask. if they where real trades the bid and ask would have gone up with it. we got suckered Thursday. they made the stock look weak.
t trades show up on your trading screen under trades just like normal trades. this only happens after hours. usually this only happens when there is very heavy trading and the system is unable to keep up. so if you are able to pull up Fridays trades you will see all of them at the end of the trading day. as these trades go thru the bid and ask will not change like it does during normal trading. just look at the bid and ask and you will know where it will be tomorrow morning. this will fool no one because during pre market tomorrow morning the bid and ask will not be in the 3s unless we get some very big news that is going to move the stock. so look to see the bid and ask around .025 where it closed Friday.
freeshrimp. everyone knows there is no after hour trading on the otc. some stocks have pre market but there is no after market. the trade where t trades from the previous day. if they where actual trades you would also see it in the bid and ask. the bid and ask did not change. they did a number on traders Thursday. if those trades would have gone thru in real time Thursday there is a good chance we might not of seen such a sell off. they made this stock look weaker then it was Thursday. they caused panic selling.
the thing that really sucks with all those t trades is the point they did not show them during normal trading. it made it look like there was a big sell off. if those trades would have gone thru real time we may not have had so many people get scared and sell that caused panic selling.
disappointed the goldman report did not come out as promised. and we need to see a good contract with an outside company. still holding all my shares but beginning to wonder.
another day another tweet and yet no update. bragged their stock is holding up good. I guess down almost 25% is good to them.
first you said the sec is going to halt this stock over the weekend. now you say it is going to draw their attention. so that means they are not going to halt it as it has not gotten their attention yet.
the biggest thing that is bothering me is kaly has not addressed the point that we are not current. you know they have to know the reason and yet they will not say anything to the share holders. any good company in my eyes would fill the investors in on what is going on. and I want to see the goldman report they said we would have today. glta
the goldman report that they said would be out by Friday would go a long way now also saying something about going current. we need something strong after yesterday.
has any one else noticed with all the pr's coming out from pura kaly and usmj none of them mention evsv any more. did the deal go bad. is that why evsv said they would have an update and never did. makes me wonder. nouv announced another 100 acre's and they could have put evsv in there easy to help control pest or something. beginning to wonder what is up with evsv.
it was not just kaly. the market as a hole took a dump end of day. Nasdaq hit a low that has not been seen since sep 2017 and possible government shut down did not help. damage control will be need. put out some good strong news in the morning and we will start to climb again. it sucked but like I said the market took a dump as a hole. those that trade by what the market is doing started to sell then we had the panic sellers follow. we are still in the same shape. we also need kaly to address when we will go current. I am sure they have been in contact with the otc. lets hope now that the farm bill has been signed we get some special news in the morning. glta.
I wish all of you would quit answering volcano. did you not learn when you where younger that if you ignore a bully most of the time they will go away. they get satisfaction knowing they are getting to you. any one that looks at his post and see's how well kaly is doing will know what he is up to. volcano alone can't change the direction of kaly. ignore his post.
no problem. my avg is .0012 up almost 3000% I am loving every minute of this. good luck.
not me never sold a single share. if you read my post I have been saying the best is yet to come.
sure would be nice to get a little something from kaly about going current. you know they must of been in contact with the otc. and get something in there about lowering the float would be a game changer. just wish full thinking. glta. still have not sold a single share.
looks like they do not think a reverse spilt will be done.
PURA - Puration 2018 Sales Exceed $1 Million Goal With 2019 Goal Set At $5 Million and NOUV Dividend Coming Sooner Than Planned
Dallas, TX -- December 20, 2018 -- InvestorsHub NewsWire -- Puration, Inc. (USOTC: PURA) (“PURA”) today released an online shareholder update that includes details on the company’s progress toward 2018 sales goals and an outlook on 2019 sales. The update also includes new information on previously announced plans to issue a dividend of Nouveau Life Pharmaceuticals, (USOTC: NOUV) (“NOUV”) stock to PURA shareholders that will speed up the issuance in addition to, management believes, improving the overall value of the dividend. Management also includes in the update highlights of business developments with US Cannabis Health partners NOUV and Kali-Extracts (USOTC: KALY). The narrative of the update can be found below in addition to finding the full update on the company’s website at www.purationinc.com.
2018 $1 Million Sales Goal
Driven primarily by the growing market penetration of our first cannabis sector beverage, EVERx CBD Sports Water, PURA has well exceeded its $1 million 2018 sales goal. In addition to throughput increasing within existing channels, EVERx is now enjoying regional expansion. PURA has recently announced new distributors in new areas around the U.S., and anticipates soon announcing its first international distribution agreements.
The recent addition of Telluride Happy Water to the PURA product line has also contributed to sales growth. PURA just announced a 100-pallet order that included a strategic marketing campaign in partnership with the Austin, Texas based distributor. We met this week to plan the marketing campaign and we are very excited to roll the program out starting in January.
The recent $1 million agreement with Generex Biotechnology, Corp. (OTCQB) to produce private label CBD infused water is a major contribution to 2019 sales. We reasonably believe we can anticipate our current channels to at least produce the same $1 million in sales in 2019 that came from those channels this year. Now add to that the Generex $1 million agreement and we are already on track to double sales in 2019. However, we except our existing channels to expand sales and we are on track with establishing new channels. So, we are optimistic that $3 million in sales next year is a reasonable goal and we’re even setting a stretch goal of $5 million in sales with the additional sales contributions anticipated from our other beverage lines to include Telluride Happy Water and THCSavor.
Upcoming Dividend Distribution
PURA recently spun-off its cannabis cultivation operation with facilities in the U.S. and Canada to NOUV. In conjunction with the spin-off, a portion of the consideration that PURA received from NOUV was slated to be converted into common stock and that NOUV common stock was to be issued to shareholders of PURA. Specifically, PURA sold its cannabis cultivation business to NOUV in exchange for a $1.2 million convertible note with a commitment that the note would promptly be converted to common shares of NOUV and that those converted shares would be distributed in a stock dividend to the shareholders of PURA. PURA and NOUV originally planned to wait for NOUV to execute a reverse spilt before executing the dividend distribution. While pursuing that objective, it became clear the execution of the reverse split would take some time. As NOUV updates its filings and executes on its business plan with the new cannabis cultivation operation, optimistically, a reverse split of NOUV might not be necessary. So, PURA and NOUV management have explored alternative options. In light of the fact that the common shares of NOUV issued to PURA shareholders will not be immediately free trading and will have to season to be free trading under an exemption from registration, PURA and NOUV have resolved to issue a dividend of preferred shares convertible into common shares. In this way, a dividend of equity can be rapidly issued and the seasoning of shares for exemption can begin. If a NOUV reverse proceeds as originally planned, then shareholders will receive the original allocation of 1 common share for every 5 shares of PURA. If a reverse proves unnecessary, then the conversion of preferred shares into common shares will be adjusted accordingly to affect an equal dividend allocation.
US Cannabis Health Joint Venture
The Joint Venture (JV) partnership with KALY and NOUV is proceeding even better than anticipated. KALY and NOUV today announced an agreement to expand NOUV’s current cultivation operations to include 100 adjacent acers dedicated to growing hemp under the new Farm Bill legalizing hemp farming and anticipated to be signed into law later today by President Trump. KALY will construct a CBD extraction facility on site based on KALY’s patented extraction process. In addition to the outdoor hemp cultivation, NOUV will build a state-of-the-art greenhouse operation intended for the development of a proprietary hemp cultivar.
Now that KALY’s filings are cleaned up with OTCMarkets and Frederick Ferri has taken the reins and CEO, the caliber of KALY’s assets and capabilities is becoming more clear to the market. KALY produces pharmaceutical grade cannabis extracts that have been involved in multiple clinical trials in addition to utilizing its patented cannabis extraction process in the production of CBD infused nutrition and wellness products to include its own Hemp4mula and CBD infused waters produced by PURA.
As PURA shareholders likely know, NOUV has a cannabis cultivation operation with facilities in the U.S. and Canada. NOUV’s objective in the partnership announced today with KALY is to develop a proprietary pharmaceutical grade hemp cultivar in addition to being a source of hemp supply for a myriad of industries in what management anticipates to be exploding demand in 2019.
KALY, NOUV and PURA are partners in US Cannabis Health for the purpose of together developing partnerships with pharmaceutical companies to develop cannabis pharmaceuticals. US Cannabis Health recently announced its first agreement with Generex Biotechnology, Corp. (OTCQB: GNBT).
To learn more about Puration, Inc., visit www.purationinc.com
To learn more about Kali-Extracts, Inc., visit www.kali-extracts.com
PURA - Puration 2018 Sales Exceed $1 Million Goal With 2019 Goal Set At $5 Million and NOUV Dividend Coming Sooner Than Planned
Dallas, TX -- December 20, 2018 -- InvestorsHub NewsWire -- Puration, Inc. (USOTC: PURA) (“PURA”) today released an online shareholder update that includes details on the company’s progress toward 2018 sales goals and an outlook on 2019 sales. The update also includes new information on previously announced plans to issue a dividend of Nouveau Life Pharmaceuticals, (USOTC: NOUV) (“NOUV”) stock to PURA shareholders that will speed up the issuance in addition to, management believes, improving the overall value of the dividend. Management also includes in the update highlights of business developments with US Cannabis Health partners NOUV and Kali-Extracts (USOTC: KALY). The narrative of the update can be found below in addition to finding the full update on the company’s website at www.purationinc.com.
2018 $1 Million Sales Goal
Driven primarily by the growing market penetration of our first cannabis sector beverage, EVERx CBD Sports Water, PURA has well exceeded its $1 million 2018 sales goal. In addition to throughput increasing within existing channels, EVERx is now enjoying regional expansion. PURA has recently announced new distributors in new areas around the U.S., and anticipates soon announcing its first international distribution agreements.
The recent addition of Telluride Happy Water to the PURA product line has also contributed to sales growth. PURA just announced a 100-pallet order that included a strategic marketing campaign in partnership with the Austin, Texas based distributor. We met this week to plan the marketing campaign and we are very excited to roll the program out starting in January.
The recent $1 million agreement with Generex Biotechnology, Corp. (OTCQB) to produce private label CBD infused water is a major contribution to 2019 sales. We reasonably believe we can anticipate our current channels to at least produce the same $1 million in sales in 2019 that came from those channels this year. Now add to that the Generex $1 million agreement and we are already on track to double sales in 2019. However, we except our existing channels to expand sales and we are on track with establishing new channels. So, we are optimistic that $3 million in sales next year is a reasonable goal and we’re even setting a stretch goal of $5 million in sales with the additional sales contributions anticipated from our other beverage lines to include Telluride Happy Water and THCSavor.
Upcoming Dividend Distribution
PURA recently spun-off its cannabis cultivation operation with facilities in the U.S. and Canada to NOUV. In conjunction with the spin-off, a portion of the consideration that PURA received from NOUV was slated to be converted into common stock and that NOUV common stock was to be issued to shareholders of PURA. Specifically, PURA sold its cannabis cultivation business to NOUV in exchange for a $1.2 million convertible note with a commitment that the note would promptly be converted to common shares of NOUV and that those converted shares would be distributed in a stock dividend to the shareholders of PURA. PURA and NOUV originally planned to wait for NOUV to execute a reverse spilt before executing the dividend distribution. While pursuing that objective, it became clear the execution of the reverse split would take some time. As NOUV updates its filings and executes on its business plan with the new cannabis cultivation operation, optimistically, a reverse split of NOUV might not be necessary. So, PURA and NOUV management have explored alternative options. In light of the fact that the common shares of NOUV issued to PURA shareholders will not be immediately free trading and will have to season to be free trading under an exemption from registration, PURA and NOUV have resolved to issue a dividend of preferred shares convertible into common shares. In this way, a dividend of equity can be rapidly issued and the seasoning of shares for exemption can begin. If a NOUV reverse proceeds as originally planned, then shareholders will receive the original allocation of 1 common share for every 5 shares of PURA. If a reverse proves unnecessary, then the conversion of preferred shares into common shares will be adjusted accordingly to affect an equal dividend allocation.
US Cannabis Health Joint Venture
The Joint Venture (JV) partnership with KALY and NOUV is proceeding even better than anticipated. KALY and NOUV today announced an agreement to expand NOUV’s current cultivation operations to include 100 adjacent acers dedicated to growing hemp under the new Farm Bill legalizing hemp farming and anticipated to be signed into law later today by President Trump. KALY will construct a CBD extraction facility on site based on KALY’s patented extraction process. In addition to the outdoor hemp cultivation, NOUV will build a state-of-the-art greenhouse operation intended for the development of a proprietary hemp cultivar.
Now that KALY’s filings are cleaned up with OTCMarkets and Frederick Ferri has taken the reins and CEO, the caliber of KALY’s assets and capabilities is becoming more clear to the market. KALY produces pharmaceutical grade cannabis extracts that have been involved in multiple clinical trials in addition to utilizing its patented cannabis extraction process in the production of CBD infused nutrition and wellness products to include its own Hemp4mula and CBD infused waters produced by PURA.
As PURA shareholders likely know, NOUV has a cannabis cultivation operation with facilities in the U.S. and Canada. NOUV’s objective in the partnership announced today with KALY is to develop a proprietary pharmaceutical grade hemp cultivar in addition to being a source of hemp supply for a myriad of industries in what management anticipates to be exploding demand in 2019.
KALY, NOUV and PURA are partners in US Cannabis Health for the purpose of together developing partnerships with pharmaceutical companies to develop cannabis pharmaceuticals. US Cannabis Health recently announced its first agreement with Generex Biotechnology, Corp. (OTCQB: GNBT).
To learn more about Puration, Inc., visit www.purationinc.com
To learn more about Kali-Extracts, Inc., visit www.kali-extracts.com
farm bill signing live on you tube this afternoon. around 2:30
for those new here. we are supposed to have a goldman sacks research report out by Friday with more info on the company. glta.
pjet and kaly both up pre market with pre market trading.
if the bid and ask hold it will be the biggest gap so far on this one. could there be news that the mm's can see that is ready to come out that we are unable to see until it is released. honestly do not know if they are able to see pending news.
any real thoughts. pjet 232 million shares traded. up 160%
kaly 194 million shares traded. up 50%
evsv 124 million shares traded. up 66%
feel like something is coming.
any real thoughts. pjet 232 million shares traded. up 160%
kaly 194 million shares traded. up 50%
evsv 124 million shares traded. up 66%
feel like something is coming.
any real thoughts. pjet 232 million shares traded. up 160%
kaly 194 million shares traded. up 50%
evsv 124 million shares traded. up 66%
feel like something is coming.
for me it is no where as hard to walk away for a hour or so. it is waiting for the next day after the market closes. now we have to wait almost sixteen hours it to open again. glta.
yep looks like selling dried up. man did they scare a lot of people out. oh well more weak hands out for the stronger hands to hold for more highs. like I said the best is yet to come. congrats to all those that held.
put out the goldman report tonight or in the morning and we run. if not I see more accumulation till it comes out. supposed to have more details about kaly in it then they have released.
KALY - Kali-Extracts Anticipates President Trump Signing Farm Bill Tomorrow To Unlock Yet Unrealized Cannabis Biotech Value
Print
KALY - Kali-Extracts Anticipates President Trump Signing Farm Bill Tomorrow To Unlock Yet Unrealized Cannabis Biotech Value
DALLAS, TX -- December 19, 2018 -- InvestorsHub NewsWire -- Kali, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) earlier today announced the new Kali Cannabis Therapies subsidiary to develop cannabis biotechnology treatment alternatives to chemical pharmaceuticals.
Kali-Extracts Releases Preclinical Research Study Results On Therapy For Respiratory Disease Driving $11 Billion Treatment Market
The Kali Cannabis Therapies announcement this morning sheds light on years of preclinical research and development results rendered from experiment with cannabis extracts derived from Kali’s patented cannabis extraction process. President Trump has indicated his intention to sign the Farm Bill legalizing hemp farming into law tomorrow, Thursday, December 20th, 2018.
“I’ve been conducting research on cannabis therapies for a variety of conditions for years under the shadow cast by outdated and government regulations,” said Frederick Ferri, CEO of Kali-Extracts. “Government policy makers are finally reaching an age of cannabis enlightenment and a clean fresh light is about to shine on all Kali-Extracts work. I expect the legalization of hemp farming to bring light on the yet unrecognized overall value of medical cannabis market. I expect Kali-Extract’s cannabis intellectual property to stand out in the crowd.”
To learn more about Kali-Extracts, Inc., visit www.kali-extracts.com
you had to know a big shake was coming. at some point the mm's need shares. always happens. like I said before with every leg up they take it down to get shares. did not sell a single share. why would any one sell before the goldman report comes out for a better idea of the big picture. even kaly said there would be more detailed info in the report.
with every step up they take it back down a little to shake the tree and get shares for the next leg up. this is great and the best is yet to come.
pjet moved to number 1 on break out boards.
you have to love it. the goldman research report isn't even out yet. that kaly said them self will explain better and in more detail on what this all means. we are going higher. it even took clay of guard. love his post.
come on baby give us that goldman research report. this is getting stronger and stronger.
ok it just hit. lets see what happens.
news still hasn't hit my trading screen. many still have not seen the news on research.